Upon joining the study, you will attend an initial visit where you will be asked to provide signed informed consent. This is a document that confirms your understanding and agreement to participate in the study.

During this visit, you will undergo a series of assessments to confirm your eligibility, including a review of your medical history and a physical examination.

You will enter a screening phase where your eligibility will be further assessed. This includes maintaining an electronic diary (eDiary) to record your pelvic pain, vaginal bleeding, and any use of rescue medication.

You will be required to demonstrate compliance with at least 75% of the eDiary entries and take only the study-provided rescue medication during this period.

Before the main treatment phase, you will enter a placebo run-in phase. During this time, you will take placebo tablets to ensure compliance with the study protocol.

Your compliance with taking the placebo tablets will be assessed, and you must achieve at least 80% compliance.

Once eligibility is confirmed, you will be randomly assigned to one of four groups. Three groups will receive different dose levels of the study medication OG-6219, and one group will receive a placebo.

The study medication or placebo will be taken orally twice a day. The dose levels for OG-6219 are 50 mg, 100 mg, or 150 mg.

You will undergo three treatment cycles, during which you will continue to record your symptoms and any use of rescue medication in the eDiary.

Your overall pelvic pain will be evaluated using a numeric rating scale, and you will attend regular study visits for assessments, including transvaginal ultrasound and blood tests.

After completing the treatment cycles, you will have follow-up visits to assess your response to the treatment and any side effects.

Final assessments will include a review of your eDiary entries, physical examinations, and laboratory tests to ensure your safety and evaluate the study’s outcomes.